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NaturalT cell receptors (TCRs) generally bind to their cognate pMHC molecules with weak
affinity and fast kinetics, limiting their use as therapeutic agents. Using phage display, we
have engineered a high affinity version of the A6 wild-type TCR (A6wt), specific for the
human leukocyte antigen (HLA-A∗0201) complexed with human T cell lymphotropic virus
type 111–19 peptide (A2-Tax). Mutations in just 4 residues in the CDR3β loop region of the
A6wt TCR were selected that improved binding to A2-Tax by nearly 1000-fold. Biophysi-
cal measurements of this mutant TCR (A6c134) demonstrated that the enhanced binding
was derived through favorable enthalpy and a slower off-rate. The structure of the free
A6c134 TCR and the A6c134/A2-Tax complex revealed a native binding mode, similar to
the A6wt/A2-Tax complex. However, concordant with the more favorable binding enthalpy,
the A6c134TCR made increased contacts with theTax peptide compared with the A6wt/A2-
Tax complex, demonstrating a peptide-focused mechanism for the enhanced affinity that
directly involved the mutated residues in the A6c134TCR CDR3β loop.This peptide-focused
enhancedTCR binding may represent an important approach for developing antigen specific
high affinity TCR reagents for use in T cell based therapies.
Keywords: human T leukocyte virus type 1, crystal structure, peptide-major histocompatibility complex, surface
plasmon resonance,T cell,T cell receptor, A6TCR, high affinityTCR
INTRODUCTION
CD8+ αβ T cells recognize mainly intracellularly expressed anti-
gens through an interaction mediated by the cell surface expressed
T cell receptor (TCR). Intracellular proteins, processed by the
proteasome into short peptides (generally 8–13 amino acids in
length), are presented to CD8+ T cells on the surface of almost all
nucleated human cells by class I major histocompatibility complex
proteins (pMHCI). TCR recognition of pMHCI initiates CD8+ T
cell activation and the adaptive immune response. The ability of
CD8+ T cells to scrutinize the intracellular environment provides
an important mechanism to target aberrant disease epitopes that
would be otherwise hidden from the immune system. Thus, CD8+
T cells play an important role during viral infections (Miles et al.,
Abbreviations: pMHC, peptide-major histocompatibility complex; RU, response
unit; SPR, surface plasmon resonance.
2010), which typically elicit strong CD8+ T cell responses, many
of which have been well-characterized, including those to HTLV-
1 (Bieganowska et al., 1999; Vine et al., 2004), although some
viruses can escape CD8+ T cell mediated clearance (Klenerman
and Zinkernagel, 1998; Overbaugh and Bangham, 2001). Cancers
too, as a result of their malignant transformation, have altered
protein expression causing the presentation of tumor-associated
peptide antigens (TAPAs) (Renkvist et al., 2001; Cole et al., 2009).
However, although these TAPAs can elicit a host CD8+ T cell
response, this is often insufficient to cause tumor rejection (Blohm
et al., 2002; Parkhurst et al., 2004). CD8+ T cell responses are
also integral to the initiation and progression of many autoim-
mune diseases, possibly through the unwanted recognition of
self-peptide antigens (Bulek et al., 2012). The TCR/pMHC inter-
action, which governs CD8+ T cell responses, is therefore an
attractive therapeutic target in many varied diseases, particularly
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in cases where a disease-associated peptide antigen “target” has
been unambiguously established.
However, unlike antibodies that can undergo somatic hyper-
mutation and bind with high affinity (K D= nM–pM) and long
half-lives (typically hours), TCRs are selected in the thymus to
bind with weak affinity (K D= 100 nM–270µM) and short half-
lives (typically seconds) (Cole et al., 2007; Bridgeman et al., 2012).
Why TCRs are selected to bind within this weak affinity range is
not fully understood, but may represent a balance between self-
tolerance and a requirement for T cell cross-reactivity (Mason,
1998; Sewell, 2012; Wooldridge et al., 2012). However, the weak
affinity and short half-lives of natural TCR/pMHC interactions
imposes limitations on the use of TCRs for targeting cell sur-
face expressed pMHCs, primarily because the short half-life is not
adequate for the delivery of therapeutic interventions to target
antigens. In order to overcome this limitation, we have recently
implemented phage display to generate TCRs with an enhanced
affinity for cognate antigen (Li et al., 2005; Dunn et al., 2006; Sami
et al., 2007; Varela-Rohena et al., 2008; Liddy et al., 2012) that can
be used to target cell surface expressed MHC molecules display-
ing any disease epitope of interest. Using this technique, we have
generated several high affinity TCRs derived from the αβ TCR A6
(A6wt) that are specific for the HTLV-111–19 peptide, presented
by HLA-A∗0201 (A2-Tax) (Li et al., 2005). High affinity TCRs
generated using this method can be used for two distinct type of
therapies. The first involves genetically reprograming host T cells
so that they express a modified TCR (adoptive therapy) (Mor-
gan et al., 2006; Varela-Rohena et al., 2008). The second involves
using a soluble high affinity TCR to deliver a therapeutic payload
intravenously (soluble therapy) (Liddy et al., 2012). The optimal
TCR affinity for these two types of therapy, in terms for retaining
specificity and reactivity, will probably be distinct and will likely
be lower for adoptive therapy because of the polyvalent nature of
T cell antigen recognition at the cell surface versus a soluble ther-
apy in which the TCR reagent will likely require a longer half-life
to effectively target intended disease markers. Understanding how
these reagents function at the molecular level is key to determin-
ing these parameters and optimizing these types of T cell directed
therapies.
Previous structural investigations of TCR/pMHC interactions
have shown that TCRs bind with a relatively conserved diago-
nal orientation (Garboczi et al., 1996; Rudolph et al., 2006), with
the α-chain focused toward the N-terminus of the peptide and
the β-chain toward the C-terminus. Although exceptions occur
(Burrows et al., 2010), this orientation enables the TCR comple-
mentarity determining region (CDR)2 loops to be positioned over
mainly the MHC surface, the CDR3 loops to be positioned primar-
ily over the peptide and the CDR1 loops positioned in between.
This binding mode, and the low native TCR binding affinity, is pre-
sumably important for maintaining T cell specificity and antigen
sensitivity, and is possibly important in T cell signaling (Adams
et al., 2011). However, we have previously shown that just a small
number of mutations in the TCR CDR loops can improve the low
natural TCR/pMHC binding affinity dramatically (Li et al., 2005;
Dunn et al., 2006; Hawse et al., 2012). Thus, it is likely that high
affinity TCRs are generated in the thymus, but they are not selected
for release into the periphery. In order to better understand the
consequences of high affinity TCR interactions, and to provide
further insight into: (1) how high affinity TCR binding is mediated
and (2) what effects this binding is likely to have on TCR specificity,
we solved the atomic structures of a high affinity TCR,A6c134, free,
and in complex with A2-Tax. By comparing this structure with the
previously published structures for the A6wt TCR (Garboczi et al.,
1996; Scott et al., 2011), we provide a molecular explanation for
the improved binding of this high affinity TCR.
RESULTS
DECONSTRUCTION OF HIGH AFFINITY A6 TCR VARIANTS SPECIFIC FOR
A2-TAX
In order to generate a high affinity version of the A6wt TCR,
we implemented phage display as previously described (Li et al.,
2005). This process generated a number of high affinity TCRs,
including the mutant A6c134 that varied from the A6wt TCR
parental sequence at only four codons, all located within the
CDR3β loop (Table 1). It has been previously determined that
the A6wt TCR binds to A2-Tax with an affinity of ∼1–3µM
and an off-rate (t 1/2) of ∼7–10 s (Davis-Harrison et al., 2005;
Armstrong and Baker, 2007; Cole et al., 2007). In contrast, the
engineered high affinity A6c134 TCR bound to A2-Tax with an
affinity of 4 nM (nearly 1000 times greater than the A6wt TCR, or
∆∆G° =−3.96 kcal/mol) and an off-rate (t 1/2) of 3900 s (>400
times longer than the A6wt TCR), as determined by surface plas-
mon resonance (SPR) (Table 1). A6c134 did not bind to other
HLA-A2 restricted peptides that were used as negative controls
in different SPR experiments, including as A2-ILAKFLHWL, A2-
ELAGIGILTV, and A2-YLEPGPVTA demonstrating that A6c134
retained peptide specificity (data not shown). In order to investi-
gate the molecular basis for how this high affinity was generated,
we used reverse engineering to construct a range of A6wt-based
TCRs containing different combinations of amino acids from the
A6c134 CDR3β sequence and, conversely, a range of A6c134-based
TCRs containing different combinations of amino acids from the
A6wt CDR3β sequence (Table 1). All of these TCRs exhibited very
similar on-rates, but showed marked differences in their off-rates
(Table 1). In general, the mutations appeared to act cooperatively
to enhance affinity. The mutation of the A6wt TCR from R102 to
Q102 had only a small effect upon binding affinity and may have
been selected because of the lower toxicity of the TCR to the TG1
phage host (Li et al., 2005).
A6c134 TCR BOUND TO A2-TAX USING A SIMILAR CONFORMATION TO
THE A6wt TCR
In order to determine the structural basis of the high affinity
binding for the A6c134 TCR, we solved the A6c134/A2-Tax com-
plex structure to 2.74 Å. Molecular replacement was successful
only in space group C121, consistent with the presence of one
molecule of the complex per asymmetric unit, and the reso-
lution was sufficiently high to show that the interface between
the two molecules was well ordered and contained well defined
electron density. The crystallographic R/Rfree factors were 22
and 26%, within the accepted limits shown in the theoretically
expected distribution (Tickle et al., 2000) (Table S1 in Supple-
mentary Material). The overall buried surface area (BSA) of
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Table 1 | Biophysical analysis of different combinations of “knock-in” and “knock-out” mutations (in bold type and underlined) of A6wt and
A6c134TCRs binding to A2-Tax.
Mutant CDR3β KD kon (s−1 M−1) koff (s−1) t1/2 (s) ∆G° (kcal/mol) ∆∆G° (kcal/mol)
A6wt AGGR 3.2µM 2.3×104 7.4×10−2 9.3 −7.49 n/a
A6c134M MGGR 1.9µM 1.8×104 3.5×10−2 20 −7.80 −0.31
A6c134S ASGR 1.8µM 2.3×104 4.1×10−2 17 −7.83 −0.34
A6c134AE ASAE 9.4 nM 2.3×104 5.2×10−4 1320 −10.94 −3.45
A6c134E MSAE 4.4 nM 5.5×104 2.2×10−4 3120 −11.39 −3.90
A6c134R MSAR 8 nM 1.9×104 1.5×10−4 4500 −11.04 −3.55
A6c134 MSAQ 4 nM 4.5×104 1.8×10−4 3900 −11.45 −3.96
Off-rates were determined by least squares fitting of single-component exponential decay equation to the decay curve following TCR binding to A2-Tax.
Half-lives were calculated using the equation t1/2 = ln2/koff.
∆∆G° =∆G° of high affinity A6c134 variant binding to A2-Tax −∆G° of A6wt binding to A2-Tax.
2445.4 Å (TCR/pMHC) was within the range observed for pre-
viously characterized TCR/pMHC interactions (Rudolph et al.,
2006). The high affinity A6c134 TCR bound with a diagonal dock-
ing geometry to A2-Tax and showed one to one stoichiometry
as previously reported of other TCR/pMHC complexes (Rudolph
et al., 2006). We observed a high level of similarity between the
A6wt/A2-Tax and A6c134/A2-Tax complexes, suggesting that over-
all conformation was unaffected by the mutations in A6c134.
Importantly, the Tax peptide conformation was virtually identi-
cal in both complexes, discounting the possibility that structural
changes in the peptide contributed to the high affinity observed
(Figures 1A,B). Similarly, the architecture of the CDR loops was
unaffected by the mutations in the A6c134 TCR (Figure 1C), and
the crossing angle of both TCRs was identical at 34° (Figure 1D)
and fell within the previously observed range (Rudolph et al.,
2006). Thus, differences in binding affinity between the A6wt and
A6c134 TCRs could not be explained by a large conformational
change in geometry, consistent with observations in similar stud-
ies with other systems (Dunn et al., 2006; Sami et al., 2007; Madura
et al., 2013).
THE A6c134 TCR CDR LOOPS UNDERGO LARGE CONFORMATIONAL
ADJUSTMENTS DURING A2-TAX ENGAGEMENT
We next solved the structure of the A6c134 TCR at 2 Å (Table S1 in
Supplementary Material; Figure 2). The crystallographic R/Rfree
factors were 23.4 and 29.5%, consistent with the expected ratio
range (Tickle et al., 2000). In many cases, although not all (Bor-
bulevych et al., 2011b; Holland et al., 2012), TCR CDR loops
have been shown to undergo numerous, and sometimes large,
conformational changes upon pMHC binding (Armstrong et al.,
2008b). Superposition of the free and the bound A6c134 TCR
showed that, although the overall conformation of the TCR was
virtually identical (Figure 2A), the CDR loops underwent sub-
stantial movements (Figure 2B). The CDR3 loops of both chains
of the A6c134 TCR were poorly ordered and could not be fully
resolved, indicating a large amount flexibility in this region of
the TCR. Although the apex of the CDR3 loops could not be
accurately located, the portions of the CDR3α and CDR3β loops
that were visible underwent large hinge movements of ∼5.9 and
∼4.6 Å, respectively (Figures 2C,D). These changes were substan-
tial compared to other structural studies in which the largest loop
FIGURE 1 |The overall conformations of A6wt and A6c134TCRs in
complex with A2-Tax are similar. (A) Comparison of peptide
conformation in the A6wt TCR (red sticks) and A6c134 TCR (yellow sticks)
complex structures looking down on top of the MHC groove (gray sticks).
(B) Comparison of peptide conformation in the A6wt TCR (red sticks) and
A6c134 TCR (yellow sticks) complex structures looking from the side of the
MHC groove (gray sticks). (C) Comparison of CDR loop conformation in the
A6wt TCR (yellow and orange ribbons) and A6c134 TCR (blue and green
ribbon) A2-Tax complex structures. (D) Crossing angle comparison of the
A6wt TCR and A6c134 TCR in complex with A2-Tax. Colors as in C.
movement observed for a human MHCI restricted TCR was 5.6 Å
(Kjer-Nielsen et al., 2002; Stewart-Jones et al., 2003). Interestingly,
a nearly identical observation was made for A6wt TCR (Scott et al.,
2011), for which the dynamics of the CDR3 loops were shown to
have a large influence on the specificity and cross-reactivity of the
TCR. This occurrence with A6c134 leads to the somewhat coun-
terintuitive conclusion that substitution of the sequence AGGR
with MSAQ in CDR3β does not greatly impact the overall dynam-
ics of the loop, and leads us to suggest that the enhanced affinity
of A6c134 was not attributable to “preorganization” of CDR3β,
i.e., the MSAQ mutation did not alter the non-bound form of the
A6c134 TCR to a conformation closer to that of the bound form.
This conclusion is consistent with the observation that the binding
www.frontiersin.org June 2013 | Volume 4 | Article 168 | 3
Cole et al. Peptide focused enhanced affinity TCR
of A6c134 to A2-Tax is characterized by a much more favorable
enthalpy change along with a less favorable entropy change (as
pre-organization would have resulted in a more favorable binding
entropy) (Armstrong and Baker, 2007; Piepenbrink et al., 2009).
The CDR1 and CDR2 loops underwent a smaller rigid body
shift and hinge movements of 2.5–4 Å (Figures 2E–H). On aver-
age, the A6c134 TCR CDR loops moved by 4.1 Å. Altogether, this
degree of conformational plasticity is high compared to other
TCRs (Armstrong et al., 2008b), and demonstrated that the A6c134
TCR undergoes a high degree of conformational melding during
binding, as does the A6wt TCR (Borbulevych et al., 2011a). These
movements enabled direct contacts between the A6c134 TCR
and A2-Tax and resolved steric clashes that would have occurred
between the unbound TCR and the MHC surface, as observed for
the A6wt TCR (Scott et al., 2011).
FIGURE 2 |The A6c134TCR CDR loops undergo a large degree of
conformational adjustment during binding to A2-Tax. Comparison of
the conformations of the A6c134 TCR CDR1, CDR2, and CDR3 loops in the
A6c134/A2-Tax complex versus A6c134 TCR free structures. (A)
Superposition of the free (cyan and yellow cartoon) and complexed (blue
and green cartoon) A6c134 TCR. (B) Superposition of the free (cyan and
yellow lines) and complexed (blue and green lines) A6c134 TCR looking
down on the A2-Tax surface (gray and yellow surface). (C) Superposition of
the free (cyan cartoon) and complexed (blue cartoon) A6c134 TCR CDR3α
loop. (D) Superposition of the free (yellow cartoon) and complexed (green
cartoon) A6c134 TCR CDR3β loop. (E) Superposition of the free (cyan
cartoon) and complexed (blue cartoon) A6c134 TCR CDR1α loop. (F)
Superposition of the free (yellow cartoon) and complexed (green cartoon)
A6c134TCR CDR1β loop. (G) Superposition of the free (cyan cartoon) and
complexed (blue cartoon) A6c134 TCR CDR2α loop. (H) Superposition of
the free (yellow cartoon) and complexed (green cartoon) A6c134TCR
CDR2β loop. Loop moments at the apex, or region of greatest movement
are shown.
THE HIGH AFFINITY BINDING OF THE A6c134 TCR WAS GOVERNED BY
INCREASED PEPTIDE CONTACTS
As the overall free and bound conformations of A6wt and A6c134
were nearly identical, we decided to investigate differences in
atomic interactions at the A6wt and A6c134 interfaces. The bind-
ing footprints of the A6wt and A6c134 TCRs on A2-Tax were
similar, but not identical, resulting in the involvement of differ-
ent peptide and MHC residues at the interface (Figures 3A,B).
Although the A6c134 TCR α-chain contained no mutations, it uti-
lized a different combination of TCR residues for binding A2-Tax
compared with A6wt. As a result, the A6c134 TCR α-chain made
a number of new and different contacts with A2-Tax compared
with the A6wt TCR (Tables S2 and S3 in Supplementary Mate-
rial; Table 2; Figures 3C,D). Thus, the mutations in the A6c134
TCR β-chain mediated a knock-on, or indirect effect resulting in
a modified binding mode for the TCR α-chain.
In contrast with the A6c134 TCR α-chain, the A6c134 β-chain
containing the mutated MSAQ motif formed a virtually identical
footprint on A2-Tax compared to the A6wt TCR (Figure 3D).
The A6c134 β-chain made a similar number of contacts with
the MHC compared to the corresponding residues in the A6wt
TCR (AGGR) (Figures 4A,B). This was reflected by the obser-
vation that the A6c134 TCR made only 11 more contacts with
the MHC surface compared to the A6wt/A2-Tax complex. How-
ever, the A6c134 TCR made 26 extra contacts with the Tax
peptide compared to the A6wt TCR, suggesting a TCR-peptide
mediated mechanism for the enhanced affinity observed. This
observation was also supported by the increase in shape com-
plementarity index (Lawrence and Colman, 1993; Reinherz et al.,
1999) (SC= 0.74) for the A6c134/A2-Tax complex compared to
the A6wt/A2-Tax complex (SC= 0.63), and is consistent with the
FIGURE 3 |The specific footprints made in the A6wtTCR/A2-Tax and
A6c134TCR/A2-Tax complex structures are unique. (A) MHC (red
surface) and peptide (yellow surface) residues that are contacted by the
A6wt TCR. (B) MHC (red surface) and peptide (yellow surface) residues that
are contacted by the A6c134 TCR. (C) A6wt TCR residues (orange and
yellow surface) that contact the pMHC. (D) A6c134 TCR residues (blue and
green surface) that contact the pMHC. Although the overall contact
footprint is similar, the A6c134 TCR makes new interactions with both the
MHC surface and the peptide.
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Table 2 | Direct contacts made by the A6wtTCR, or A6c134TCR CDR3
loops.
TCR vdW (3.2–4 Å) H-bonds (≤3.4 Å)
A6wt TCR Thr93 0 1
CDR3α Thr98 2 1
Asp99 15 3
Ser100 7 2
Trp101 5 0
Gly102 0 0
A6c134 TCR Thr93 1 0
CDR3α Thr98 2 1
Asp99 15 2
Ser100 12 2
Trp101 9 0
Gly102 3 0
A6wt TCR Arg95 0 1
CDR3β Leu98 14 1
Ala99 0 0
Gly100 1 0
Gly101 6 2
Arg102 14 1
Pro103 5 0
A6c134 TCR Arg95 2 1
CDR3β Leu98 17 0
Met99 4 0
Ser100 6 0
Ala101 17 1
Gln102 7 0
Pro103 11 0
Mutated residues are shown in red.
observation that the enhanced affinity of A6c134 was enthalpically
driven as noted above (Armstrong and Baker, 2007; Piepenbrink
et al., 2009).
Overall, the mutated MSAQ motif directly accounted for 11 of
the 37 new contacts with the surface of A2-Tax (Figures 4C,D;
Table 2). For instance; the A99–M99 mutation generated 4
additional van der Waals contacts (Figure 5A), G100–S100
generated an additional 5 additional van der Waals contacts
(Figure 5B) and G101–A101 generated 10 additional contacts
(Figure 5C), with A2-Tax. Interestingly, the R102–Q102 muta-
tion resulted in the loss of seven van der Waals contacts and
one hydrogen bond (Figure 5D). However, the overall affin-
ity was stronger for A6c134 (MSAQ) compared to A6c134R
(MSAR) suggesting that the R102–Q102 mutation contributed
indirectly to binding. Thus, 26 new contacts were generated
through indirect interactions with non-mutated residues in the
c134 TCR. The majority of these (21 new contacts) were made
between non-mutated residues in the c134 TCR CDR3α and
CDR3β loops demonstrating that the proximity of residues to
the mutated MSAQ motif in the CDR3β loop was probably
important for enabling the formation of these new interactions
(Table 2).
FIGURE 4 | Increased peptide contacts between A6c134TCR and
A2-Tax mediate the high affinity binding. Specific contacts (<4 Å) made
by residues 99–102 in the TCR CDR3β-chain of either: AGGR (A6wt TCR) or
MSAQ (A6c134 TCR). (A) Contacts (dotted lines) between the A6wt TCR
CDR3β chain, residues 99–102 (AGGR) (shown in orange sticks) and the
MHC (gray sticks). (B) Contacts (dotted lines) between the A6c134 TCR
CDR3β chain, residues 99–102 (MSAQ) (shown in green sticks) and the
MHC (gray sticks). (C) Contacts (dotted lines) between the A6wt TCR
CDR3β chain, residues 99–102 (AGGR) (shown in orange sticks) and the
peptide (yellow sticks). (D) Contacts (dotted lines) between the A6c134 TCR
CDR3β chain, residues 99–102 (MSAQ) (shown in green sticks) and the
peptide (yellow sticks). Contacts between the A6c134 and the MHC remain
similar to the A6wt/A2-Tax complex whereas A6c134-peptide contacts are
increased.
DISCUSSION
Thymic selection generates T cells that express TCRs with a
weak binding affinity (K D= 100 nM–270µM) for cognate anti-
gen (Cole et al., 2007; Bridgeman et al., 2012). Presumably, this
affinity range is important to ensure host protection against
foreign invaders, whilst maintaining tolerance to self-antigens
from a T cell repertoire of around 25 million (Arstila et al.,
1999). In order to perform this function, growing evidence sug-
gests that TCRs must be highly cross-reactive within the con-
fines of MHC-restriction (Mason, 1998; Sewell, 2012; Wooldridge
et al., 2012). We have previously shown that it is possible to
enhance TCR binding affinity using phage display (Li et al.,
2005). These engineered high affinity TCRs represent a poten-
tially useful tool to target specific disease molecules, such as cancer
(Liddy et al., 2012) or HIV (Varela-Rohena et al., 2008). How-
ever, how enhanced affinity affects TCR binding and specificity
is not fully understood, and there are likely multiple mecha-
nistic routes through which affinity can be enhanced. A greater
understanding of such mechanisms is particularly important
when developing T cell therapies that involve genetically mod-
ifying T cells with enhanced affinity TCRs or when using sol-
uble high affinity TCR therapies, to limit potentially dangerous
self-reactivity.
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FIGURE 5 |The MSAQ motif (A6c134TCR) makes an increased the
number of contacts with A2-Tax compared to AGGR (A6wtTCR). (A)
Differences in contacts made by A99 (A6wt TCR in orange sticks, left panel)
compared to M99 (A6c134 TCR in green sticks, right panel). (B) Differences
in contacts made by G100 (A6wt TCR in orange sticks, left panel) compared
to S100 (A6c134 TCR in green sticks, right panel). (C) Differences in contacts
made by Gly101 (A6wt TCR in orange sticks, left panel) compared to Ala101
(A6c134 TCR in green sticks, right panel). (D) Differences in contacts made
by R102 (A6wt TCR in orange sticks, left panel) compared to Q102 (A6c134
TCR in green sticks, right panel). In all cases, VdW contacts are shown as
black dotted lines (4 Å cut-off) and hydrogen bonds/salt bridges are shown
as red dotted lines (3.4 Å cut-off). Peptide residues are shown as yellow
sticks and MHC residues are shown as gray sticks.
In order to explore how TCR CDR3 loop mutations could influ-
ence TCR binding and enhance affinity, we generated a modified
TCR with nearly 1000-fold enhanced binding affinity by mutating
just four residues in the TCR CDR3β loop. Despite the enhanced
binding affinity, the A6c134 TCR utilized a native binding mode
with diagonal binding geometry as observed for other TCR/pMHC
complexes (Rudolph et al., 2006). This observation is similar to
other high affinity TCR structures that have been reported previ-
ously (Dunn et al., 2006; Sami et al., 2007; Madura et al., 2013).
Furthermore, comparing the structures of the free and complexed
A6c134 TCR demonstrated that the TCR CDR3 loops underwent a
reduction in conformational flexibility upon ligand binding simi-
lar to that observed with the A6wt TCR. Thus, despite the mutation
of two glycines in the CDR3β loop, high affinity binding did not
seem to result from preorganization of the TCR binding site.
We observed that the total number of contacts across the inter-
face was greater for A6c134/A2-Tax than for A6wt/A2-Tax. For
instance, in the A6c134/A2-Tax complex, there were a total of
154 contacts, including 72 to peptide and 82 to the MHC. In the
A6wt/A2-Tax complex, there were total of 117 contacts, including
46 to peptide and 71 to the MHC. Both the MHC and peptide
were involved in generating these new contacts, and they were
mediated by both mutated and non-mutated TCR residues. How-
ever, the majority of the new contacts arose from interactions
between the peptide and the c134 TCR CDR3 loops. Thus, we
concluded that higher affinity was mediated predominantly by
new TCR-peptide interactions. This conclusion, that new con-
tacts mediated the stronger binding affinity, is consistent with
previous thermodynamic analyses, which showed that the A6c134
TCR bound to A2-Tax with a substantially more favorable enthalpy
compared to the A6wt TCR (∆∆H=−10 kcal/mol) (Armstrong
et al., 2008a; Piepenbrink et al., 2009).
Our generation of a high affinity TCR that contained muta-
tions at only four residues in the CDR3β loop compared to the
wt TCR sequence raises the question of why high affinity TCRs
are not naturally selected in the thymus (Holler et al., 2003).
Clearly, the structural framework of the TCR allows for high
affinity binding, and the mutations we have identified fall within
the rearranged gene segment of the TCR rather than the pre-
defined germline encoded segments. Furthermore, the mutations
in the TCR CDR3β chain generated an increase in peptide con-
tacts within the boundaries of the native A6wt TCR binding mode
and would thus be unlikely to alter MHC-restriction. Therefore, it
seems very likely that high affinity TCR variants could be gener-
ated during the process of TCR rearrangement in the thymus. Yet
such high affinity TCRs have not been observed during the periph-
eral immune response, implying that they are negatively selected
(Holler et al., 2003). Presumably, this process is designed to limit
self-reactivity. However, weaker affinity TCRs may also be selected
to ensure a level of T cell cross-reactivity capable of fully protect-
ing the host against all possible disease epitopes (Mason, 1998;
Sewell, 2012; Wooldridge et al., 2012). In support of this notion,
our data indicate that A6c134 and other high affinity TCRs can
retain extremely high levels of specificity, and may be more specific
than their wild-type parents (Laugel et al., 2005; Dunn et al., 2006;
Madura et al., 2013). Generally, therapeutic TCRs do not need the
capacity to be cross-reactive as they are designed to target a sin-
gle disease epitope. This difference in desired function (immune
response versus specific therapy) may represent an opportunity to
improve the affinity of natural TCRs in a safe manner. Thus, our
structural investigation of A6c134/A2-Tax, showing that the high
affinity interaction was mediated by a native binding mechanism
that was peptide-focused, may represent an important approach
for developing antigen specific high affinity TCR reagents for use
in T cell based therapies.
MATERIALS AND METHODS
PHAGE DISPLAY
Selection of high affinity A6wt TCR variants was performed as
previously described (Li et al., 2005).
PROTEIN PURIFICATION
A2-Tax peptide-MHC complexes was prepared as previously
described (Garboczi et al., 1992), by expressing HLA-A∗0201
heavy-chain truncated at residue Pro-276 and β2 microglobulin
separately in E. coli in the form of inclusion bodies, followed
by in vitro refolding with synthetic peptide. pMHC for binding
analysis was prepared similarly, but with the MHC fused to a
biotinylation tag (Cull and Schatz, 2000) which was biotinylated
in vitro by the BirA enzyme (O’callaghan et al., 1999). Disulfide-
linked A6c134 TCR was prepared as previously described (Boulter
et al., 2003; Li et al., 2005).
BINDING ANALYSIS BY SURFACE PLASMON RESONANCE (BIACORE™)
Binding analysis was performed on a Biacore™ 3000 machine
using a CM-5 (research grade) chip as previously described (Cole
et al., 2008; Miles et al., 2011). Streptavidin was immobilized
on all flow cells using amine coupling to a level of >1000 RU
(response units). Biotin tagged peptide-MHC was flowed over
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the streptavidin coated surface at a concentration of approxi-
mately 10µg/ml until ∼150 RU pHLA was bound. Control sur-
faces were coated with non-cognate pMHCs (A2-ILAKFLHWL,
A2-ELAGIGILTV, and A2-YLEPGPVTA) or were left coated with
streptavidin. Kinetic binding data were generated using the KIN-
JECT program to inject 10 nM TCR over the flow cells. Data were
analyzed using BIAevaluation™ software by kinetic fitting to cal-
culate kon and koff rates. Binding affinities were calculated using
the following equation: K D= koff/kon.
CRYSTALLIZATION AND X-RAY DATA COLLECTION
A6c134/A2-Tax crystals were grown in MES 25 mM pH 6.5, 24%
PEG 3350 and 10 mM NaCl; A6c134 free crystals were grown in
MES 25 mM pH 6.5, 24% PEG 3350 and 10 mM NaCl. All crys-
tals were soaked in 30% ethylene glycol before cryo-cooling. Data
were collected at 100 K at the Advanced Photon Source at Argonne
National Laboratory, USA. Reflection intensities were estimated
with the XIA2 package (Winter, 2010) and the data were scaled,
reduced, and analyzed with SCALA and the CCP4 package (Col-
laborative Computational Project, Number 4, 1994). Structures
were solved with molecular replacement using PHASER (McCoy
et al., 2007). Sequences were adjusted with COOT (Emsley and
Cowtan, 2004) and the models refined with REFMAC5. Graphi-
cal representations were prepared with PYMOL (Delano, 2002).
The reflection data and final model coordinates were deposited
with the PDB database (A6c134/A2-Tax, PDB: 4FTV; A6c134 free,
PDB: 4GRM).
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